SustainabilitySASB Index
Sustainability Disclosure Topics & Accounting Metrics
| TOPIC | ACCOUNTING METRIC | CODE | Note |
|---|---|---|---|
| Safety of Clinical Trial Participants | Discussion, by world region, of management process for ensuring quality and patient safety during clinical trials | HC-BP-210a.1 | CROs that meet standards in compliance with the laws and regulations of each country applicable to Sawai Group companies are selected. Especially, in the US, on site monitors are used to oversee study procedures for trials to assure procedures are completed and documented per GCP. |
| Number of FDA Sponsor Inspections related to clinical trial management and pharmacovigilance that resulted in: (1) Voluntary Action Indicated (VAI) and (2) Official Action Indicated (OAI) | HC-BP-210a.2 | Nothing that has not been solved | |
| Total amount of monetary losses as a result of legal proceedings associated with clinical trials in developing countries | HC-BP-210a.3 | The main markets of Sawai group are Japan and the United States, with very little business in developing countries. | |
| Access to Medicines | Description of actions and initiatives to promote access to healthcare products for priority diseases and in priority countries as defined by the Access to Medicine Index | HC-BP-240a.1 | No business in priority countries |
| List of products on the WHO List of Prequalified Medicinal Products as part of its Prequalification of Medicines Programme (PQP) | HC-BP-240a.2 | Not applicable WHO Public Assessment Reports - Medicines |
|
| Afordability & Pricing | Number of settlements of Abbreviated New Drug Application (ANDA) litigation that involved payments and/or provisions to delay bringing an authorized generic product to market for a defined time period | Not disclosed | |
| Percentage change in: (1) average list price and (2) average net price across U.S. product portfolio compared to previous year | HC-BP-240b.2 | Not disclosed | |
| Percentage change in: (1) list price and (2) net price of product with largest increase compared to previous year | HC-BP-240b.3 | Not disclosed | |
| Drug Safety | List of products listed in the Food and Drug Administration’s (FDA) MedWatch Safety Alerts for Human Medical Products database | HC-BP-250a.1 | Available via the FDA Adverse Reporting Website MedWatch: The FDA Safety Information and Adverse Event Reporting Program |
| Number of fatalities associated with products as reported in the FDA Adverse Event Reporting System | HC-BP-250a.2 | Available via the FDA Adverse Reporting Website MedWatch: The FDA Safety Information and Adverse Event Reporting Program |
|
| Number of recalls issued, total units recalled | HC-BP-250a.3 | Sawai Pharmaceutical: ESG Data (Social) |
|
| Total amount of product accepted for take-back, reuse, or disposal | HC-BP-250a.4 | Not disclosed | |
| Number of FDA enforcement actions taken in response to violations of current Good Manufacturing Practices (cGMP), by type | HC-BP-250a.5 | No FDA inspections in 2020 | |
| Counterfeit Drugs | Description of methods and technologies used to maintain trace ability of products throughout the supply chain and prevent counterfeiting | HC-BP-260a.1 | Sawai Pharmaceutical: We have introduced tamper-evident labels. Sawai Pharmaceutical Press release |
| Discussion of process for alerting customers and business partners of potential or known risks associated with counterfeit products | HC-BP-260a.2 | Sawai Pharmaceutical: In the event Sawai were to be made aware of the existence of a counterfeit Sawai product on the market, Sawai would contact the Ministry of Health, Labour and Welfare concerning the steps to take. |
|
| Number of actions that led to raids, seizure, arrests, and/or filing of criminal charges related to counterfeit products | HC-BP-260a.3 | ESG Data (Governance) | |
| Ethical Marketing | Total amount of monetary losses as a result of legal proceedings associated with false marketing claims | HC-BP-270a.1 | Not disclosed |
| Description of code of ethics governing promotion of off-label use of products | HC-BP-270a.2 | Sawai Pharmaceutical: Sawai Pharmaceutical Corporate Philosophy |
|
| Employee Recruitment, Development & Retention | Discussion of talent recruitment and retention efforts for scientists and research and development personnel | HC-BP-330a.1 | Description at the bottom* |
| (1) Voluntary and (2) involuntary turn over rate for: (a) executives/seniormanagers, (b) mid-level managers, (c) professionals, and (d) all others | HC-BP-330a.2 | Sawai Pharmaceutical: Employee turnover, retention rate of new graduates (after 3 years of employment) ESG Data (Social) |
|
| SupplyChain Management | Percentage of (1) entity's facilities and (2) Tier 1 suppliers' facilities participating in the Rx-360 International Pharmaceutical Supply Chain Consortium audit program or equivalent third-party audit programs for integrity of supply chain and ingredients | HC-BP-430a.1 | Percentage of (1) 0% Percentage of (2) 0% |
| Business Ethics | Total amount of monetary losses as a result of legal proceedings associated with corruption and bribery | HC-BP-510a.1 | Sawai Pharmaceutical ESG Data (Governance) |
| Description of code of ethics governing interactions with health care professionals | HC-BP-510a.2 | Sawai Pharmaceutical: Sawai Pharmaceutical Corporate Philosophy |
| ACTIVITY METRIC | CODE | Note |
|---|---|---|
| Number of patients treated | Sawai Pharmaceutical: Accounting for about 8% of the volume of drugs sold domestically (according to our analysis 2020) |
|
| Number of drugs (1) in portfolio and (2) in research and development (Phases1-3) | HC-BP-000.B | (1) Number of drugs in portfolio Sawai Pharmaceutical: ESG Data (Social) (2) Number of drugs in research and development stage (Phases 1-3) Sawai Pharmaceutical: Planning to launch of over 85 products in the next three years. Long-Term Vision and Mid-Term Business Plan |
*
Sawai Pharmaceutical:
[Quantitative situation]
ESG Data (Social)
[Qualitative situation]
- Internships in R&D positions are offered to volunteers during recruitment activities for new employees.
The training includes online group work on company outlines, lectures on formulation technology, and learning what is required for generic drugs.
An understanding of Sawai Pharmaceutical's R&D is gained since prior to entry into the company. - In the introductory training, new employees receive lectures from the management group, in order to create a sense of unity and team spirit with the early penetration of Sawai Pharmaceutical's vision.
- Recruitment page